NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price, Forecast & News

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Cyclacel Pharmaceuticals shares reverse split on the morning of Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.04. View Cyclacel Pharmaceuticals' Earnings History.

Cyclacel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Cyclacel Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals.

News coverage about CYCC stock has trended extremely positive on Sunday, according to InfoTrie. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals earned a media sentiment score of 5.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Cyclacel Pharmaceuticals.

Some companies that are related to Cyclacel Pharmaceuticals include Acer Therapeutics (ACER), DiaMedica Therapeutics (DMAC), Edesa Biotech (EDSA), Adamis Pharmaceuticals (ADMP), Alimera Sciences (ALIM), Teligent (TLGT), Celsion (CLSN), Akari Therapeutics (AKTX), Zosano Pharma (ZSAN), Jaguar Health (JAGX), Cassava Sciences (SAVA), OTCMKTS:EMBI (EMBI), Zafgen (ZFGN), Generex Biotechnology (GNBT) and VIVUS (VVUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include McEwen Mining (MUX), Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Exelixis (EXEL), Bausch Health Companies (BHC), Mateon Therapeutics (MATN), SLS International (SLS) and Caladrius Biosciences (CLBS).

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYCC stock can currently be purchased for approximately $0.60.

Cyclacel Pharmaceuticals has a market capitalization of $10.23 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-7,290,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Cyclacel Pharmaceuticals employs 14 workers across the globe.View Additional Information About Cyclacel Pharmaceuticals.

The official website for Cyclacel Pharmaceuticals is http://www.cyclacel.com/.

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]